We are international
Donate
TEXT SIZE   

Please note: There was a high level of background noise at the venue. Many of these videos have had the audio altered in an attempt to reduce this noise.

ASCO 2006 Webcasts COPY
    next      view all

Introduction and Overview
An Overview of the Role of Novel Therapies in Untreated Myeloma
Dr. Sundar Jagannath of St. Vincent's Cancer Center in New York discusses the importance of first line novel therapies in attaining complete remission; the importance of complete remission in overall survival; peripheral neuropathy.

IMIDs - Thalidomide (Thalomid®) and Lenalidomide (Revlimid®)
Thal plus dex vs dex alone as initial therapy for newly diagnosed MM
A multicenter, randomized, double-blind, placebo-controlled trial.

Dr. S. Vincent Rajkumar
Mayo Clinic, Rochester, MN
ASCO abstract no. 7517
Symposium Presenter

Oral lenalidomide plus melphalan and prednisone (R-MP) for newly diagnosed MM.
Dr. Antonio Palumbo
University of Torino, Torino, ITALY
ASCO Abstract #7518
ASCO Symposium Presenter

Prediction of response to therapy with clarithromycin/lenalidomide/dexamethasone (BIRD) in MM.
Dr. Ruben Niesvizky
New Presbyterian Hospital
Weill Cornell Medical Center
New York, NY
ASCO Abstract #7530
Symposium Presenter

Comparison of lenalidomide with dexamethasone to dex alone in pts who've received prior thalidomide
Comparison of lenalidomide in combination with dexamethasone to dexamethasone alone in patients who have received prior thalidomide in relapsed or refractory multiple myeloma.

Dr. Michael Wang
M.D. Anderson Cancer Center
Houston, TX

Lenalidomide + high-dose dex provides improved overall survival compared to high-dose dex alone
for relapsed or refractory MM: Results of a North American phase III study (MM-009)

Dr. Donna M. Weber
M.D. Anderson Cancer Center
Houston, TX
ASCO abstract no. #7521
Symposium Presenter

Correlation of bone marrow angiogenesis and response to thalidomide Dexamethasone in MM
Dr. Shaji Kumar
Mayo Clinic
Rochester, Minnesota

Bortezomib (Velcade®)
Single-agent bortezomib in previously untreated MM:
Results of a phase II multicenter study.
Dr. Paul Richardson
Dana Farber Cancer Institute
Boston, MA

Dose-escalating & pharmacologic study of bortezomib in adult cancer pts with impaired renal function
Dr. Daniel Mulkerin
University of Wisconsin
School of Medicine
Madison, WI

Combination Therapies
Total Therapy III Update
High CR and near CR rate with bortezomib incorporated into up-front therapy of MM with tandem transplant.

Dr. Bart Bartlogie
Myeloma Institute for Research and Therapy
University of Arkansas for Medical Sciences
Little Rock, AK

    next      view all